Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...
Business Insider2d
Novo Nordisk’s Strategic Share Repurchase Moves
Novo Nordisk (NVO) has released an update. Novo Nordisk has announced a significant transaction under its 2024 share repurchase program, acquiring 6.31 million B shares from Novo Holdings for DKK 4.74 ...
Business Insider2d
Novo Nordisk Expands 2024 Share Repurchase Program
Novo Nordisk (NVO) has released an update. Novo Nordisk has announced the continuation of its ambitious 2024 share repurchase program, now initiating an additional buyback of up to DKK 3.14 billion.
thedailyupside3d
Novo Nordisk’s Doing Brilliantly, Just Not Brilliantly Enough
Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...
Business Insider3d
Novo Nordisk Executives Show Confidence with Share Purchases
Novo Nordisk (NVO) has released an update. Novo Nordisk has disclosed share transactions by its board members and executives, highlighting a significant purchase of 1,400 American Depositary Receipts ...
Novo Nordisk Reports Strong Growth in 2024
Novo Nordisk ( (NVO) ) has released its Q3 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Novo ...
Novo Nordisk CFO Says 2025 Sales Could See High-Teens Percentage Growth
"This is a forward-looking statement, mathematically based, and we'll come back with the more detailed guidance come early February 2025," Knudsen said. He said that absolute sales growth last year ...
NBC Los Angeles6d
Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...
With Novo Nordisk success, is there a "Nokia risk" for Denmark?
This week, 60 Minutes traveled to Denmark to report on Novo Nordisk, the pharmaceutical company that's behind the popular ...
FiercePharma10d
Novo Nordisk hit with FDA write-up over production issues at critical semaglutide plant
Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this past spring. | The FDA issued a ...
The Motley Fool14d
Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?
Novo Nordisk has achieved great success in weight management thanks to its diabetes and obesity care medications, Ozempic and Wegovy. Viking Therapeutics is looking to make inroads in the obesity ...
Nasdaq15d
This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)
Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity care. The company develops a long line of blockbuster glucagon-like ...